BCIQ Profiles

Company Profile Report
1117 Pdev QTs
BioCentury & Getty Images

Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac 

By BioCentury Staff
Nov 18, 2020 | 2:32 AM GMT
Updated on Nov 18, 2020 at 3:03 AM GMT

BrainStorm sees path forward for ALS therapy despite Phase III miss
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02

Read the full 506 word article

How to gain access

Continue reading with a
two-week free trial.